1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid.

5

2. The method of claim 1 wherein said corticosteroid is selected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, betamethasone valerate.

10

- 3. The method of claim 1 wherein tazarotene is applied as a 0.1% gel.
- 4. The method of claim 1 wherein said corticosteroid is a mid- or highpotency corticosteroid.

15

- 5. The method of claim 4 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone acetonide.
- 6. A method for treating psoriasis in a human subject by topically
  applying to the psoriatic skin of said subject an effective amount of tazarotene and
  an effective amount of a corticosteroid.
  - 7. The method of claim 6 wherein tazarotene is applied as a 0.1% gel.
- 25 8. The method of claim 7 wherein said corticosteriod is a cream.
  - 9. The method of claim 8 wherein said corticosteroid is a mid- or high-potency corticosteroid.

- 10. The method of claim 9 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone.
  - 11. The method of claim 6 wherein tazarotene is administered once
- daily in the evening and the corticosteroid is administered once daily in the morning.